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Abstract
Background: Global gene expression profiles of bovine kidney epithelial cells regulated by sodium
butyrate were investigated with high-density oligonucleotide microarrays. The bovine microarray
with 86,191 distinct 60mer oligonucleotides, each with 4 replicates, was designed and produced
with Maskless Array Synthesizer technology. These oligonucleotides represent approximately
45,383 unique cattle sequences.
Results: 450 genes significantly regulated by butyrate with a median False Discovery Rate (FDR)
= 0 % were identified. The majority of these genes were repressed by butyrate and associated with
cell cycle control. The expression levels of 30 selected genes identified by the microarray were
confirmed using real-time PCR. The results from real-time PCR positively correlated (R = 0.867)
with the results from the microarray.
Conclusion: This study presented the genes related to multiple signal pathways such as cell cycle
control and apoptosis. The profound changes in gene expression elucidate the molecular basis for
the pleiotropic effects of butyrate on biological processes. These findings enable better recognition
of the full range of beneficial roles butyrate may play during cattle energy metabolism, cell growth
and proliferation, and possibly in fighting gastrointestinal pathogens.
Background
The most common short-chain fatty acids (SCFA) are nat-
ural microbial fermentation products in the gastrointesti-
nal tract. SCFA, including propionic, butyric and valeric
acids, each with three, four and five carbons, respectively,
contribute to the energy balance of all mammalian species
[1,2]. The major sources of these carbohydrates are hemi-
celluloses and fiber, which consists of plant cell wall
polysaccharides such as cellulose and pectins [1]. In rumi-
nants, SCFA are a major energy source and contribute up
to 70% of their energy requirements [2]. Beyond their
nutritional impact, SCFA, especially butyrate, have a mul-
titude of cellular regulatory effects that modulate cell dif-
ferentiation, proliferation, and motility. All three major
components of SCFA induce apoptosis and inhibit cell
proliferation, however, butyrate has the most potent effect
[3,4]. Roles for butyrate have been established in cell dif-
ferentiation, proliferation, motility and in particular
induction of cell cycle arrest and apoptosis [5-7]. Apopto-
sis is a genetically regulated cellular suicide mechanism
that plays a crucial role in development and in the defense
of homeostasis of animals [8]. The mechanism(s) by
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which butyrate induces cellular differentiation and sup-
presses growth has not been elucidated. Similarly, the
mechanism through which butyrate and other short-chain
fatty acids induce the cell cycle regulatory and apoptotic
effects and the mechanism by which the decision between
cell death and survival is arbitrated are poorly understood
[9-12].
In a previous study [13], potential biological roles of
butyrate were investigated using the established Madin-
Darby bovine kidney epithelial cell line (MDBK). The
study focused on determining whether normal bovine
cells in a standard cell culture condition were sensitive to
the growth inhibitory effects of butyrate. The data sug-
gested that sodium butyrate (SB) could induce apoptosis
and cell cycle arrest in MDBK cells. Up to 38% of cells
became apoptotic after 24 hours of treatment with 10 mM
of butyrate. Butyrate also blocked the surviving cells at
two distinct stages, G1 and M/G2. However, more studies
are needed to better understand the relationship between
butyrate and alterations in the expression of genes
involved in cell cycle, apoptosis, and transcriptional regu-
lation. Recent advances in high-throughput genomic tools
such as microarray technology allowed us to examine the
genome-wide effects of sodium butyrate on MDBK cells.
Results
Butyrate Induces Cell Cycle Arrest and Hyperacetylation 
of Histone 3 in MDBK Cells
We previously reported that butyrate induced cell cycle
arrest in MDBK cells [13]. Prior to microarray analysis, the
butyrate induced cell cycle arrest was reconfirmed. As
shown in Figure 1, after butyrate treatment for 24 h, cell
population profiles changed significantly. In the surviving
cell population there was a significant increase in the
number of cells in G1 (cells with 2C DNA contents)
whereas those in S phase (cells falling between the 2C and
4C DNA contents) were decreased. This result confirmed
our prior observation that cells were arrested at the G1/S
boundary and DNA replication was blocked by the
butyrate treatment. We also confirmed accumulation of
acetylated histone 3 (H3) due to the butyrate treatment
(Fig. 2). H3 acetylation was selected as the marker for the
accumulation of acetylated histones because H3 is one of
the core histones (H2A, H2B, H3, and H4), and is highly
conserved across a wide range of organisms. The antibody
against the acetyl H3(lys18) is also readily available com-
mercially. To determine whether these biochemical
attributes of butyrate were also observed in MDBK cells,
two specific antibodies, the monoclonal antibody against
the acetyl H3 and the monoclonal antibody against
acetyl-phospho H3, were used to evaluate the histone
deacetylase inhibitory activity of butyrate. Histone
deacetylase (HDAC) inhibitors induce the hyperacetyla-
tion of nucleosomal histones. Evidence suggested that H3
phosphorylation is restricted to a small fraction of highly
acetylated H3 histones. H3 phosphorylation is cell cycle
dependent and may be associated with induced FOS and
MYC oncogenes. No evidence indicates H3 phosphoryla-
tion directly results from HADC inhibitory activities. As
shown in Fig. 2, butyrate treatment induced not only
accumulation of hyperacetylation of H3 (Lys18) but also
phosphor (Ser10)-acetyl (Lys9) H3. The quantified rela-
tive densities from the Western Blot show approximately
a 2-fold increase of acetylated H3 protein and 2-fold
increase of phosphor-acetyl H3 (Fig. 2B). Therefore it is
reasonable to assume the increase detected by the anti-
body against phosph(Ser10)-Acetyl (lys9)-H3 is mostly
due to the acetylation of H3 induced by butyrate.
Butyrate Induces Profound Changes in Gene Expression in 
MDBK Cells
In our previous study [13] and prior to the current micro-
array experiment, we monitored butyrate induced cell
death and cell cycle arrest in MDBK cells in a time/dose-
dependent manner using flow cytometry and Western
blotting. For the purpose of this investigation and for
determining the differential gene expression induced by
butyrate, we selected a single dose proven to be able to
generate maximum biological impacts in cell cycle arrest.
Due to research budget constraints, we selected only a sin-
gle time point as the initial global expression screening.
We intend to verify the genes identified with the microar-
ray in a time/dose-dependent manner using real-time RT-
PCR in subsequent studies. We identified 450 genes sig-
nificantly regulated by sodium butyrate at a very stringent
false discovery rate (FDR) = 0% (see Additional file 1).
However, when relaxing the stringency threshold to FDR
= 10%, which should still be acceptable in most cases,
there were 3662 genes significantly regulated (3662/
45383 = 8%, data not shown). This percentage was con-
sistent with a previous report [6] in which the authors
used cDNA microarrays consisting of ~8000 sequences to
demonstrate that approximately 7% of sequences assayed
exhibited alteration by butyrate in human colon carci-
noma cells.
Cell Cycle Control
The single largest category of genes regulated by butyrate
(103) was cell cycle control related (Table 1). Butyrate
repressed the vast majority of these genes including cyc-
lins, cyclin-dependent kinases, histone deacetylases, heli-
cases, chromosomal structure proteins as well as kinesins.
Ubiquitin conjugating enzyme E2 C was also down-regu-
lated. However, Max interacting protein 1 (MXI1) was up-
regulated 12.6-fold by butyrate.
Apoptosis and Extracellular Matrix
Fourteen genes related to apoptosis and extracellular
matrix (ECM) were significantly regulated by butyrateBMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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(Table 2). Generally, butyrate induced pro-apoptotic
genes and repressed anti-apoptotic genes. Inhibin, beta A
(INHBA) and adrenomedullin were among the induced
genes while apoptosis inhibitors such as survivin and
FAIM were down-regulated. Interestingly, Insulin-like
growth factor 2 (IGF2) was up-regulated while IGF bind-
ing proteins 4 and 6 were down-regulated. Collagens,
such as COL5A2 and COL3A1, and extracellular matrix
protein Spondin 1 were repressed by butyrate while tissue
inhibitor of metalloproteinase 2 (TIMP2) was signifi-
cantly up-regulated.
Real-Time RT PCR
Thirty genes that represent different expression levels and
functional classes were selected for real-time RT-PCR con-
firmation (Table 3). The real-time PCR data generally con-
firmed the microarray analysis. Linear regression analysis
demonstrated a strong positive correlation between the
two technological platforms with R = 0.867.
Discussion
Cell cycle regulatory and apoptotic effects of butyrate and
other short-chain fatty acids at the cellular and molecular
levels in normal bovine cells have not been studied thus
far but would serve as a principle launch point to validate
the need for further study of these phenomena in cattle.
Furthermore, utilization of particular signaling pathways
in regulating cellular function or inducing gene expres-
sion appears to be dependent on, among other factors, the
type of stimulus and cell examined. In our previous study,
Cell cycle progressions determined by flow cytometry Figure 1
Cell cycle progressions determined by flow cytometry. Histogram plot of flow cytometry analysis of A: control cells; B: the 
cells treated by 10 mM sodium butyrate. Deconvolution of the DNA histogram using automated cell cycle analysis with 'Cyl-
chred' software of C: control cells; and D: the cells treated by 10 mM sodium butyrate. Insert: Mean ± SEM (n = 3 per treat-
ment; **: P < 0.01. G1/G0: cells in G1/G0 cell cycle phases; S: cells in S cell cycle phase; M/G2: cells in M/G2 cell Cycle phases). 
2C and 4C: two and four copies of DNA content respectively.BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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Butyrate induced hyperacetylation of histone 3 (H3) Figure 2
Butyrate induced hyperacetylation of histone 3 (H3). This figure is representative of three experiments (n = 3). A: Protein from 
different samples was separated by SDS PAGE on two identical 4 to 20% polyacrylamide gradient gels. One gel was stained 
with SimpleBlue (Invitrogen) and one was transferred to a membrane for Western blotting with monoclonal anti- acetyl-phos-
pho H3 and anti- acetyl H3 antibodies; B: Western Blots from three experiments were quantified with NIH Image software. 
The relative densities were measured and corrected with the protein density. H3: histone 3. **: P < 0.01.BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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Table 1: Cell cycle-related genes significantly regulated by butyrate.
Accession Annotation Fold q-value*(%)
TC265170 Aurora kinase A (AURKA) 0.17 0
TC266385 Aurora kinase B (AURKB) 0.18 0
TC278061 Aurora-A kinase interacting protein (AURKAIP1) 0.19 0
TC281252 BUB1 budding uninhibited by benzimidazoles 1 homolog (BUB1) 0.10 0
TC281450 BUB1 budding uninhibited by benzimidazoles 1 homolog beta (BUB1B) 0.06 0
TC280420 CDC28 protein kinase regulatory subunit 2 0.02 0
TC292959 CDC2L1 0.04 0
TC293208 CDC45 cell division cycle 45-like 0.09 0
TC278776 Cell division cycle 2, G1 to S and G2 to M (CDC2) 0.12 0
TC285500 Cell division cycle 25A (CDC25A) 0.11 0
TC271610 Cell division cycle 25B isoform 3 0.14 0
TC294713 Cell division cycle 2-related 0.16 0
TC278478 Cell division cycle and apoptosis regulator 1 0.17 0
TC294633 Cell division cycle associated 2 (CDCA2) 0.08 0
TC292945 Cell division cycle associated 8 0.17 0
TC263741 Cell division cycle protein 20 homolog (p55CDC) 0.10 0
CK975861 Centromere protein F (350/400kD) 0.06 0
TC261165 Centromere protein-A (CENP-A) 0.09 0
TC267900 Centromeric protein E (CENP-E protein) 0.11 0
TC279457 CHK1 checkpoint homolog 0.16 0
TC293183 Chromatin assembly factor 1 subunit A (CAF-1) 0.20 0
TC268367 Chromobox protein homolog 5 0.10 0
TC297649 Chromodomain helicase DNA binding protein 3 0.14 0
TC265382 Chromosome condensation protein G 0.06 0
TC262952 Cyclin A2 0.17 0
TC265945 Cyclin B1 (CCNB1) 0.06 0
TC278429 Cyclin B2 (CCNB2) 0.22 0
TC262075 Cyclin G1 0.07 0
TC262855 Cyclin-dependent kinase 4 0.15 0
TC265450 Cyclin-dependent kinase inhibitor 2C 0.22 0
TC278545 Cyclin-dependent kinases regulatory subunit 1 (CKS-1) 0.09 0
TC284317 Defective in sister chromatid cohesion homolog 1 0.06 0
TC290880 Deoxythymidylate kinase (thymidylate kinase) (LOC506946) 0.15 0
TC273170 Discs large homolog 7 (DLG7) 0.22 0
TC265245 DNA directed RNA polymerase III polypeptide D 0.12 0
TC284361 DNA helicase (Blooms syndrome protein, RecQ protein-like 3) 0.11 0
TC267167 DNA mismatch repair protein Msh3 (mut S homolog 3) 0.24 0
TC278497 DNA polymerase epsilon p17 subunit gene 0.03 0
TC279954 DNA polymerase, alpha 2 (70kD subunit)(POLA2) 0.11 0
CK945922 DNA repair and recombination protein RAD54-likex 0.06 0
TC282404 DNA repair protein RAD51 homolog 1 0.11 0
TC290487 E2F transcription factor 4 0.11 0
TC282153 Establishment of cohesion 1 homolog 2 0.13 0
TC265789 Extra spindle poles like 1 (ESPL1) 0.08 0
TC291293 flap structure-specific endonuclease 1 (FEN1) 0.18 0
TC266990 G-2 and S-phase expressed 1 0.23 0
TC270253 GAJ protein (MND1) 0.07 0
TC292293 General transcription factor IIIC, polypeptide 2, beta 110kDa 0.24 0
BG688435 H/ACA ribonucleoprotein complex subunit 4 (Dyskerin, DKC1) 0.11 0
TC269917 Helicase, lymphoid-specific 0.13 0
TC267482 Histone deacetylase 8 0.15 0
TC276662 Histone H2A.Z 0.08 0BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
Page 6 of 14
(page number not for citation purposes)
TC272233 Huntingtin interacting protein 2 (HIP2) 0.25 0
TC267608 Inner centromere protein 0.11 0
TC279078 Katanin p80 (KATNB1) 0.16 0
TC295304 Kinesin family member 11 0.23 0
TC294618 Kinesin family member 14 0.20 0
TC267353 Kinesin family member 20A 0.12 0
TC260588 Kinesin-like protein KIF22 0.09 0
TC291455 Kinesin-like protein KIF23 (Mitotic kinesin-like protein 1) 0.07 0
TC278220 Kinesin-like protein KIF2C (Mitotic centromere-associated kinesin) 0.19 0
TC266372 Kinetochore associated 2 0.15 0
TC284307 Lamin B1 (LMNB1) 0.05 0
TC277820 MAD2 mitotic arrest deficient-like 1 0.07 0
TC288554 Max interacting protein 1 (MXI1) 12.55 0
TC261106 MCM4 (CDC21 homolog) DNA replication licensing factor 0.14 0
TC264981 Minichromosome maintenance deficient 3 (MCM3) 0.10 0
TC277221 Minichromosome maintenance deficient 5 (MCM5, CDC46 homolog) 0.17 0
TC265572 Minichromosome maintenance deficient 6 (MCM6) 0.09 0
TC263581 Minichromosome maintenance protein 2 0.14 0
TC290639 Minichromosome maintenance protein 3 associated protein 0.16 0
TC293069 Mitotic spindle associated protein p126, MAP126 0.04 0
TC298939 M-phase phosphoprotein 1 (mitotic kinesin-like protein, MPHOSPH1) 0.13 0
TC260429 MutS homolog 6 0.21 0
TC266513 NEK2 (NIMA-related protein kinase 2) 0.13 0
TC278195 Nuclear ubiquitous casein and cyclin-dependent kinases substrate (P1) 0.19 0
TC279654 Nucleolar and spindle associated protein 1 0.08 0
TC274682 Nucleolin 0.10 0
TC293949 Origin recognition complex subunit 1 0.23 0
TC281941 PDZ-binding kinase (PBK) 0.15 0
TC278800 pescadillo homolog 1, containing BRCT domain (PES1) 0.17 0
TC289876 Proliferating cell nuclear antigen (PCNA) 0.09 0
TC263003 Proliferation-associated 2G4 0.16 0
TC276620 Proteasome (prosome, macropain) 28 subunit, alpha 0.21 0
TC260258 Proteasome subunit, beta type 8 (PSMB8) 0.14 0
TC292683 Protein C20orf172 (C20orf172) 0.06 0
TC300533 Protein regulator of cytokinesis 1 0.07 0
TC279370 Protein regulator of cytokinesis 1 (PRC1) 0.11 0
TC282034 RAD51 associated protein 1 (RAD51AP1) 0.21 0
TC280581 Replication factor C (activator 1) 3 (RFC3) 0.19 0
TC265859 Replication factor C (activator 1) 4 (RFC4) 0.03 0
TC263936 Ribonucleoside-diphosphate reductase M2 chain (RRM2) 0.17 0
TC275004 Scaffold attachment factor B2 0.20 0
TC266542 Sin3 associated polypeptide p30 (SAP30) 0.22 0
TC282970 SMC4 structural maintenance of chromosomes 4-like 1 (SMC4L1) 0.13 0
TC290192 Spindle pole body component 24 (kinetochore protein Spc24) 0.09 0
TC281963 Spindle pole body component 25 (kinetochore protein Spc25) 0.14 0
TC279153 Topoisomerase (DNA) II binding 0.05 0
TC278044 Transcription elongation regulator 1 0.09 0
TC281731 Transducin (beta)-like 1X-linked receptor 1 (TBL1XR1) 0.08 0
TC277942 Ubiquitin-conjugating enzyme E2 C (Ubiquitin-protein ligase C) 0.14 0
TC280380 Wee1-like protein kinase 0.16 0
TC279802 XPMC2 prevents mitotic catastrophe 2 homolog 0.21 0
* q-value is a percentage of a gene identified by chance as being significant.
Table 1: Cell cycle-related genes significantly regulated by butyrate. (Continued)BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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an important question asked and answered was whether
normal bovine cells in a standard cell culture condition
are sensitive to the growth inhibitory effects of
butyrate[13]. In this follow-up study, we utilize microar-
ray technique to examine the genome-wide effects of
sodium butyrate on MDBK cells as an important compo-
nent of our efforts to understand the mechanisms of this
phenomenon. Our data presented in this report indicate
that the effects of butyrate are mediated through coordi-
nated changes in gene expression that are the outcome of
interactions between transduction pathways. We identi-
fied 450 genes significantly regulated by sodium butyrate
at a very stringent false discovery rate (FDR) = 0%. How-
ever, since many of the genes have no direct links to the
cell cycle arrest or apoptosis, their involvement in these
biological effects certainly warrants more investigation.
Therefore, instead of speculating, our discussion is con-
centrated primarily in cell cycle and apoptosis.
Sodium butyrate (SB) exerts a very broad range of effects
on many biological pathways via its inhibitory ability on
HDAC. SB is a potent inducer of a G1 cell cycle arrest. It
also provokes apoptosis by activating both the death
receptor and intrinsic apoptotic pathway. It regulates the
cell cycle via down-regulation of cyclins and activation of
CDK [14]. In addition, it was reported that butyrate mod-
ulates host immune responses by activating neutrophils
[15] and enhancing IL-4-dependent IgE production [16].
Butyrate has immune suppression [17] and anti-inflam-
matory properties, in part by suppressing nuclear factor
NF-κB activity [18-20]. Regulation of enzymes involved in
cytoskeleton and cell membranes by butyrate has also
been reported [21]. The majority of its effects directly
result from HDAC inhibition. However, butyrate appears
to be involved in signal transduction via its own receptor
GPR41, resulting in inosityl 1,4,5-triphosphate genera-
tion, intracellular Ca2+ release, ERK1/2 activation, and
inhibition of cAMP accumulation [22]. Because of their
ability to inhibit cell proliferation, HDAC inhibitors
(HDI) including butyrate have been extensively exploited
as anti-tumor agents [23]. Butyrate appears to have pleio-
tropic effects on various biological processes. The genes
we identified (see Additional file 1), which fall within a
broad range of functional categories, appeared to provide
the molecular basis for its pleiotropic effects.
Butyrate seems able to inhibit all class I HDACs [24]. It
would be safe to assume that, like trichostatin A (TSA),
butyrate can indeed inhibit the activities of HDAC8 and
HDAC10, even though butyrate may have a different
mechanism of action. Our studies suggested that butyrate
indeed repressed histone deacetylase 8 (HDAC8) mRNA
expression. The missing link is why this inhibition of
enzymatic activities in turn down-regulates their own
expression in mRNA levels. In mouse neural cells, it was
observed that HDAC inhibitors affect the expression of
HDACs themselves [18]. In these cells, both TSA and SB
indeed elevated the expression of HDAC1, HDAC3,
HDAC5 and HDAC6 whereas mRNA levels of HDAC 2
and HDAC7 did not change. The mRNA levels of HDAC8
and HDAC10 were not detectable in these cells. While the
mechanism and biological relevance of HDI regulation of
HDAC expression remains unclear, it appears that there
indeed exists an auto-regulatory feedback loop to the
expression of several HDACs after their activities are
inhibited.
It appears that the effects of HDI such as TSA and SB on
MMP (matrix metalloproteinase) expression are specific
to cell types. In mouse 3T3 fibroblasts, TSA represses
MMP2 expression [25], while in human colonic cells
DHD/K12, MMP production is inhibited by butyrate [26].
In HT1080 tumor cells, both protein and mRNA levels of
TIMP1, TIMP2, MMP2 and MMP9 are increased by
butyrate treatment [27]. Based on their data of limited
modulation of MMP by butyrate in human SW1116 colon
Table 2: Apoptosis- and ECM-related genes significantly regulated by butyrate
Accession Annotation Fold q-value (%)
CK975939 Tissue factor pathway inhibitor-2 (TFPI2) 0.07 0
TC266701 Fas apoptotic inhibitory molecule (FAIM) 0.07 0
CK965146 Collagen alpha 2(V) chain precursor (COL5A2) 0.12 0
TC281170 Tissue factor pathway inhibitor precursor (TFPI) 0.12 0
TC281607 Baculoviral IAP repeat-containing 5 (BIRC5) 0.16 0
TC261916 procollagen, type III, alpha 1 (COL3A1) 0.16 0
TC279824 spondin 1(SPON1) 0.19 0
TC289874 Insulin-like growth factor-binding protein 6 (IGFBP6) 0.2 0
TC275158 Insulin-like growth factor-binding protein 4 (IGFBP4) 0.21 0
TC265483 Programmed cell death 11(PDCD11) 0.27 0
TC276741 Insulin-like growth factor 2 (IGF2) 6.5 0
TC265993 Inhibin, beta A (INHBA) 9.48 0
TC277385 Adrenomedullin (ADM) 12.47 0
TC260960 Tissue inhibitor of metalloproteinase 2 (TIMP2) 14.05 0BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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cancer cells [28], Emenaker et al suggested that SCFA, such
as those derived from dietary fiber, may protect against
invasive colon cancer through stimulation of TIMP and
inhibition of uPA (plasminogen activator, urokinase)
activities rather than their effects on MMP activities. In the
present study, we found that both TIMP2 and MMPs, such
as MMP1, MMP9 and MMP13, were induced by butyrate.
The expression levels of TIMP2 induced by butyrate are
similar (10.82, 11.28, and 14.05 folds, respectively) as
detected by the three sequences that represent this gene on
the microarray [TIGR: TC260960, TIGR: TC289409 and
TIGR: TC289410]. However, changes in MMP levels were
not considered significant due to the high stringency cut-
off used in this study (FDR = 0%). The net effect of this
induction on both MMPs and their inhibitor (TIMP2) is
still unclear. TIMP2 can promote apoptosis in an in vivo
colorectal cancer model yet can protect B16 melanoma
cells from apoptosis [29]. The elucidation of the mecha-
nisms involved in controlling these distinctly opposing
phenotypic effects of TIMP2 is of paramount importance.
Insulin-like growth factor binding proteins (IGFBP) mod-
ulate IGF action and regulate cell growth and apoptosis by
preventing IGF from interacting with their own receptors.
In our study, insulin-like growth factor (IGF-2) was upreg-
ulated by SB, which is consistent with other published
data [30]. Our microarray and real-time RT-PCR results
confirmed that IGFBP6, which has a 100-fold higher affin-
ity for IGF2 than IGF1 [31], was down-regulated by
butyrate. It seems paradoxical that while IGF2 is up-regu-
lated significantly by SB, its highest affinity binding pro-
tein is down-regulated. Our results may suggest different
functions of various IGFBP members in regulating apop-
tosis and cell cycle progression. It would be intriguing to
see how IGFBP exert their actions in cell growth and apop-
tosis via an IGF-independent fashion.
Despite the fact that the effect of HDAC inhibitors such as
SB on the expression of cell cycle regulatory genes, such as
cyclins and cyclin-related kinase (CDK), were docu-
mented and a few attempts were made to use high-
Table 3: Comparison of gene expression levels between microarray and real-time RT-PCR
Accession Annotation Microarray* Real-time PCR**
TC281450 BUB1 budding uninhibited by benzimidazoles 1 homolog beta (BUB1B) 0.1 0.1
TC266701 Fas apoptotic inhibitory molecule (FAIM) 0.1 0.3
TC277820 MAD2 mitotic arrest deficient-like 1 variant (MAD2L1) 0.1 0.1
TC261165 Centromere protein A (CENPA) 0.1 0.2
TC289876 Proliferating cell nuclear antigen (PCNA) 0.1 0.1
TC290192 Spindle pole body component 24 (SPBC24) 0.1 0.2
TC269605 Hepatocyte growth factor (scatter factor, HGF) 0.1 0.4
TC267353 Kinesin family member 20A (KIF20A) 0.1 0.1
TC260258 Proteasome subunit, beta type 8 (PSMB8) 0.1 0.2
TC262855 Cyclin-dependent kinase 4 (CDK4) 0.1 0.6
TC290639 Minichromosome maintenance protein 3 associated protein (MCM3AP) 0.2 0.5
TC289874 Insulin-like growth factor-binding protein 6 (IGFBP6) 0.2 0.3
TC262471 Heat shock 90kD protein 1, alpha (HSP90AA1) 0.2 0.5
TC295998 Activator of S phase kinase 0.3 0.3
TC277755 CSE1 chromosome segregation 1-like (CSE1L) 0.3 0.4
TC261112 Profilin 1 (PFN1) 0.4 0.4
TC294142 β-catenin (CTNNB1) 1.4 5.8
TC260308 GM2 ganglioside activator protein (GM2A) 2.3 6.6
TC267034 similar to LIM domain containing 2 (LIMD2) 2.3 4.2
TC292975 unknown 2.5 17.1
TC276824 Dual specificity protein phosphatase 1 (MKP-1) 2.8 6.6
TC260543 Cathepsin D (CTSD) 3.0 5.1
TC277986 Cathepsin L precursor (CTSL) 3.2 2.7
TC276574 Protease, serine, 11 [IGF binding] (PRSS11) 3.8 11.2
TC298909 Serine/threonine kinase 32C (STK32C) 4.3 26.2
TC265800 Activating transcription factor 3 (ATF3) 4.5 10.2
TC277745 CITED2 6.3 47.6
TC276741 Insulin-like growth factor 2 (IGF2) 6.5 100.0
TC280815 Matrix metalloproteinase 13 (MMP13) 8.3 87.8
TC265993 Inhibin, beta A (INHBA) 9.5 82.8
* fold change (microarray) = mean background-adjusted, normalized signal intensity from the butyrate treated group divided by mean background-
adjusted, normalized signal intensity from the control group.
** fold change (real-time PCR): expression in the control group was set at 1.0. The values below 1.0 indicated down-regulation by butyrate.BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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throughput approaches, such as microarrays [6], differen-
tial display [32] and SAGE, to study the effects of HDAC
inhibitors on cell cycle control, the extent of the effect of
these inhibitors on cell proliferation and cell cycle has not
been fully realized in part due to limited gene representa-
tion on these microarrays [19,30,33,34]. Due to signifi-
cant differences in gene representation, species,
microarray platforms, and data analysis tools used in
these studies, a direct comparison between our results and
those published is seemingly difficult. In general, our
results are in good agreement with published reports. For
example, we detected ~8% of all genes were significantly
regulated by butyrate in bovine MDBK cells, which is con-
sistent with a previous report [6] in which the authors
used cDNA microarray consisting of ~8000 sequences to
demonstrate that approximately 7% of sequences assayed
exhibited alteration by butyrate in human colon carci-
noma cells. Down-regulation of cyclins, PCNA, CDKs,
and upregulation of IGF2, MMPs, and TIMP2 were also
confirmed by previous reports [19,34]. However, many
genes, such as Aurora kinases, BUB1 and BUB1B, centro-
mere proteins, kinesins, Max interacting protein 1
(MXI1), minichromosomal maintenance deficient pro-
teins (MCMs), and spindle pole body components were
not previously recognized to be regulated by SB. Our
efforts in this study are among the first to systematically
categorize the butyrate-regulated genes related with cell
cycle control with a genome-wide approach in farm ani-
mals. While the vast majority of these genes are down-reg-
ulated, MXI1 is up-regulated. As a key component of the
mitotic checkpoint, MXI1 binds with MAX to form a
sequence-specific DNA-binding protein complex and acts
Correlation between levels of gene expression measured by microarray and real-time RT-PCR Figure 3
Correlation between levels of gene expression measured by microarray and real-time RT-PCR. The R = 0.867 (R2 = 0.76) was 
calculated using log-transformed values of the fold change obtained for the 30 selected genes (n = 60).BMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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as a transcriptional repressor. Up-regulation of MXI1 by
SB could result in down-regulation of cyclins, which in
turn negatively regulates centromere proteins.
Accumulation of cells with 2C and 4C DNA contents sug-
gests inhibition by butyrate of cell cycle at G1 and M/G2
phases and suggests that a common responding element
in genes responsive to the treatment of butyrate is
required for progression of both phases G1 and M/G2.
This observation is also consistent with the previous
report that the inhibition of G1 progression by butyrate is
not restricted to a specific mitogenic signaling pathway
[35], but may also include the inhibitory effect on initia-
tion of DNA replication. In this report, multiple genes
such as minichromosome maintenance (MCM) proteins
2, 3, 4, 5, and 6, as well as Orc1 (Origin Recognition Com-
plex largest subunit) are significantly down-regulated. The
products of these genes has been shown to be rate limiting
for initiation of DNA replication in eukaryotic cell lines
and are essential for the assembly of the pre-replication
complex (pre-RC) [36-38]. This finding indicates that in
someway, butyrate treatment directly targets these genes
and down regulates the genes that are essential for initia-
tion of DNA replication. CDC2/Cdk1 and related cyclins
are also significantly down-regulated. At least four roles
have now been recognized for cyclin A activated Cdk1
protein kinases in regulating cell cycle events. First, Cdk2/
cyclin A is responsible for activating pre-replication com-
plexes at the beginning of S-phase in order to begin DNA
synthesis [39]. Second, Cdk1/cyclin A inhibits assembly
of new pre-replication complexes during S-phase [39] by
inactivating Cdc6 [40]. Third, Cdk2/cyclin A is required
for the G2 to M-phase transition [41]. Finally, Li and
DePamphilis [14] recently revealed that Cdk1/cyclin A is
required for preventing Orc1 in mammals or ORC in
Xenopus from binding to chromatin during mitosis. Our
results show that targeted destruction of cdc6 and cdc2/
cdk1 may be involved in the apoptosis and cell cycle arrest
induced by butyrate. They are consistent with the growing
body of evidence suggesting that disruption of the coordi-
nation between regulation of DNA synthesis and cyclin-
dependent kinase activity is an important feature of apop-
tosis. It is of importance and interest for us to understand
the mechanism(s) of how butyrate targets these genes and
causes these changes in gene expressions. However, it will
require a great deal of efforts and certainly is out of the
scope of this report.
Understanding the mechanism of butyrate in affecting
apoptosis, cell proliferation and differentiation and espe-
cially the difference of its mode of action compared to
other HDAC inhibitors will facilitate designing novel and
more potent HDAC inhibitors that target specific cellular
processes that are dysregulated in neoplastic cells. Dissec-
tion of the pathways regulated by butyrate will provide a
basis for better utilization of its anti-tumor, anti-meta-
static, immune-mediating, and anti-inflammatory proper-
ties. In addition, butyrate has been shown to up-regulate
transcription levels of muslins, which are the major com-
ponents of gastrointestinal mucosa considered to be the
first line of defense against pathogens [42]. Because of its
ability to affect functions of monocyte-derived dendritic
cells and macrophage [17] and to activate neutrophils,
butyrate and its related biological pathways could be
manipulated to fight against gastrointestinal pathogens.
Up-regulation of glutathione S-transferases [43,44], genes
known to be involved in defense against oxidative stress,
by butyrate provides evidence of a favorable modulation
of toxicological defense systems. The results presented in
this paper not only help to better dissect HDAC inhibition
and mechanism in apoptosis and cell cycle control but
also help to understand ruminant metabolism and physi-
ology, which in turn could lead to improvement in energy
efficiency of cattle.
Conclusion
The present research identified 450 genes significantly reg-
ulated by sodium butyrate in bovine kidney epithelial
cells. The genes related to multiple signal pathways such
as cell cycle control and apoptosis were presented. The
profound changes in gene expression elucidate the molec-
ular basis for the pleiotropic effects of butyrate on biolog-
ical processes. The results presented in this paper can
provide clues on the mechanism of histone deacetylase
inhibition by butyrate and resulting alterations in the
expression of genes involved in cell cycle, apoptosis, and
transcriptional regulation. Since butyrate functions as
both a nutrient and signaling molecule regulating the cell
growth and proliferation, these findings enable better rec-
ognition of the full range of roles butyrate may play dur-
ing cattle energy metabolism, cell growth and
proliferation.
Methods
Cell Culture and Treatments
The Madin-Darby bovine kidney epithelial cells (MDBK,
American Type Culture Collection, Manassas, VA., Cata-
log No. CCL-22) were cultured in Eagle's minimal essen-
tial medium supplemented with 5% fetal bovine serum
(Invitrogen, Carlsbad, CA) in 25 cm2 flasks with medium
renewal twice per week. Cell cultures were maintained in
a water-jacked incubator with 5% CO2 at 37°C. Sub-culti-
vations were performed when cells attained 80 to 90 %
confluence, according to the product information sup-
plied by American Type Culture Collection. At approxi-
mately 50% confluence (during the exponential phase),
the cells were treated with 10 mM of sodium butyrate for
24 h (Calbiochem, San Diego, CA. Three replicate flasks of
cells for both treatment and control groups (a total of 6
samples) were used for the flow cytometry and microarrayBMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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experiments. The harvested cells were snap frozen in liq-
uid N2 and stored at -80°C until RNA extraction.
Flow Cytometric Analysis of Cells
The detailed procedures were described in a previous pub-
lication [13]. Briefly, cells collected by trypsinization were
washed and resuspended in PBS buffer. Two volumes of
ice-cold 100% ethanol were added drop wise into tubes
and mixed with cells in suspension by slow vertexing.
After incubation with RNase I, cells were then stained with
propidium iodide (PI). Measuring the fluorescence by
flow cytometry provided a measure of the amount of PI
taken up by the cells and, indirectly, the amount of DNA
content. Cell DNA content was analyzed using a flow
cytometer (FC500, Beckman Coulter, Palatine, IL) and
collected data were analyzed using Cytomics RXP (Beck-
man Coulter). At least 10,000 cells per sample were ana-
lyzed.
Preparation of Cell Extracts and Western Blot Analysis
Preparations of cells and cell extracts, SDS-PAGE and
Western Blot analysis were described previously [13].
Briefly, the protein from different samples was separated
by SDS PAGE on two identical 4 to 20% polyacrylamide
gradient gels. One gel was stained with SimpleBlue (Invit-
rogen) and one was transferred to a membrane and
probed with monoclonal anti- acetyl-phospho H3 and
anti- acetyl H3 antibodies. The target bands on the West-
ern Blots from three experiments were quantified with a
NIH Image software. The relative densities were measured
and corrected with the stained protein density.
Isolation of Total RNA
Total RNA was extracted using Trizol following the manu-
facturer's recommendations (Invitrogen). Trace genomic
DNA in the crude total RNA samples was removed by
incubation with 4–10 units DNase I per 100 µg total RNA
(Ambion, Austin, TX) at 37°C for 30 min. Total RNA was
further purified using an RNeasy Mini kit (Qiagen,
Valenica, CA). The concentration of the total RNA was
determined using a NanoDrop ND-1000 spectrophotom-
eter (NanoDrop Technologies, Rockland, DE) and RNA
integrity was verified using a Bioanalyzer 1000 (Agilent,
Palo Alto, CA).
Generation of Biotin-labeled cRNA
Biotin-labeled cRNA was generated with a modified pro-
cedure of the Superscript Choice System (Invitrogen) for
double-strand (ds) cDNA synthesis followed by in vitro
transcription. Briefly, the 1st strand cDNA was synthesized
from 4.0 µg total RNA by 1.0 unit SuperScript II reverse
transcriptase (Invitrogen) in the presence of 100 pmoles
T7 promoter Oligo dT primer. After 2nd strand synthesis,
the DNA was purified with a DNA Clean & Concentrator-
5 kit (Zymo Research, Orange, CA) and eluted with 8 to
16 µl of deionized (dd) H2O. The recovered ds cDNA was
further concentrated down to 3 µl by a speed vacuum
device. cRNA was synthesized with a MEGAscript in vitro
Transcription kit (Ambion). The in vitro transcription reac-
tion was carried out in a total volume of 23.0 µl consisting
of 3.0 µl of ds cDNA, 2.3 µl 10X Ambion reaction buffer,
2.3 µl 10X Ambion T7 enzyme mix, and 15.4 µl NTP labe-
ling mix (7.5 mM ATP, 7.5 mM GTP, 5.625 mM UTP,
5.625 mM CTP and 1.875 mM biotin-16-UTP and 1.875
mM biotin-11 CTP). The in vitro transcription reaction
was incubated at 37°C for ~16 hours in a thermocycler.
The cRNA was purified with an RNeasy mini kit (Qiagen).
Generally, 40 to 60 µg of cRNA can be obtained from 4.0
µg of input total RNA. The size range of the cRNA,
expected to be between 300 to 3000 bp with the maxi-
mum intensity centered at least 1000 bp, was verified
using a Bioanalyzer 1000. The biotinylated cRNA was
fragmented to 50 to 200 bp by heating cRNA in a buffer
consisting of 40 mM Tris-acetate, pH 8.0, 100 mM potas-
sium acetate, and 30 mM magnesium acetate at 95°C for
35 min.
Oligonucleotide Microarray, Hybridization, Image 
Acquisition and Data Analysis
The bovine microarray platform used was described previ-
ously [45]. Briefly, a total of 86,191 unique 60mer oligo-
nucleotides were designed and synthesized it in situ using
photo deprotection chemistry [46]. Each unique oligonu-
cleotide was repeated 4 times on the array (a total of
~340,000 features). These oligonucleotides represented
45,383 unique bovine sequences/genes, including 40,808
Tentative Consensus sequences (TCs) from TIGR Bos tau-
rus gene index [47] and 4,575 singletons.
The microarrays were pre-hybridized with 1X MES hybrid-
ization buffer (100 mM MES, 1.0 M Na+, 20 mM EDTA,
0.01% Tween20), 40 µg herring sperm DNA and 200 µg
acetylated BSA at 45°C for 15 min followed by hybridiza-
tion with 10 µg denatured and fragmented cRNA per
microarray at 45°C for 16 – 20 h with constant rotation.
After hybridization, the microarrays were immediately
washed extensively under non-stringent conditions (6×
SSPE, 0.01% Tween20) at room temperature (RT) fol-
lowed by a stringent wash (100 mM MES salt and free acid
solution, 0.1 M Na+, 0.01% Tween20) at 45°C. After the
final rinse with the non-stringent wash buffer, the micro-
arrays were stained with 1× Stain buffer (100 mM MES, 1
M Na+, 0.05% Tween20, 50 mg/ml of BSA, and 1 mg/ml
of Cy3-streptavidin) at RT for 25 min. The stain buffer was
removed and the microarrays were rinsed once more with
non-stringent wash buffer. The microarrays were immedi-
ately dried under a stream of argon gas and scanned using
an Axon GenePix 4000B scanner (Molecular Devices
Corp., Union City, CA) at 5 µM resolution. The data were
extracted from the raw images using NimbleScan softwareBMC Genomics 2006, 7:234 http://www.biomedcentral.com/1471-2164/7/234
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(NimbleGen, Madison, WI). The control and butyrate
treatment each had 3 replicates and a total of 6 microar-
rays were used in the experiment (GEO Accession
GSE3970). The microarray data are available as accession
GSE3970 in the Gene Expression Omnibus repository at
the National Center for Biotechnology Information [48].
Relative signal intensities (log2) for each feature were gen-
erated using the Robust Multi-Array Average (RMA) algo-
rithm [49,50]. The data were processed based on quantile
normalization method [51] using the R package [52]. This
normalization method aims to make the distribution of
intensities for each array in a set of arrays the same. The
method assumes that a quantile-quantile plot of two data
vectors with the same distribution will have a straight
diagonal line. The method performed better in dealing
with bias and reducing variability across arrays compared
to other methods [51]. The background-adjusted, normal-
ized, and log transformed intensity values were then ana-
lyzed using the Significance Analysis of Microarrays
method [53] with two-class unpaired design (SAM version
2.20 [54]). SAM is the most popular method for microar-
ray analysis with 635 citations of the original publication
as of October 2004 [55]. SAM ranks genes based on a
modified  t-test statistic. The unique features of SAM
include implementing permutation testing, and the abil-
ity to estimate a global false discovery rate (FDR, an
expected percentage of false positives among the claimed
positives) and a gene error chance (q-value). A sequence
was declared to be significant when it met a stringent
median false discovery rate (FDR) cutoff at 0 % (see Addi-
tional file 1). A BLAST search was conducted for all
sequences that met the threshold to remove possible
redundancy. When a gene was represented by multiple
sequences, the fold change with q  value of only one
sequence was selected to represent this gene.
Real-time RT-PCR
Real-time RT-PCR analysis was carried out with the iQ
SYBR Green Supermix kit (Biorad) using 200 nM of each
amplification primer (see Additional file 2) and the 1st-
strand cDNA (80 ng of the input total RNA equivalents)
in a 25 µl reaction volume. The amplification was carried
out on an iCycler iQ™ Real Time PCR Detection System
(BioRad) with the following profile: 95°C – 60s; 40 cycles
of 94°C-15s, 60°C -30s, and 72°C -30s. The melting
curve analysis was performed for each primer pair. Expres-
sion levels of β-actin remained constant (within 0.5 Ct
between samples) and were used as endogenous controls.
Relative gene expression data were calculated using the
2∆∆CT method [56].
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